Recent Updates
Recently added Catalysts

L-arginine

Phase 2

Sepsis | Unknown | Infectious Disease |Novartis AG|Trials Updated: Jan 29, 2013

L-arginine development status

Highest phase Phase 2 run by Emory University (NCT02536170)
Phase scored for NVSPhase 1
Registered trials 3 across 3 sponsors since Jan 2013

L-arginine target and mechanism

ModalityUnknown

Also known as L-arginine-HCl

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment8

FDA Designations

No designations recorded

L-arginine clinical trials

L-arginine · 1 trial · 2 indications

Early Phase 1 1
NCT01775020Dose-response Study of Arginine Supplementation in Severe SepsisSepsis
COMPLETED8 Analytics
EARLY_PHASE1COMPLETED
Dose-response Study of Arginine Supplementation in Severe Sepsis
Sepsis
NCT017750208
Unlock trial analytics

Study Endpoints

Primary Endpoints

Nitric oxide synthesis
8 hours

Nitric oxide synthesis at step-wise increasing doses of L-arginine infusion. Following a 2h baseline measurements, 3 stepwise increasing arginine doses each provided for 2h will be tested for the effect on NO synthesis.

Secondary Endpoints

hemodynamics
8 hours
blood parameters
8 hours
gastric perfusion
8 hours
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP

Treatment Arms

ArmTypeDescription
L-arginineEXPERIMENTALL-arginine

Interventions

NameTypeDescription
L-arginineDIETARY_SUPPLEMENT -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Written informed consent from close relative * Age \> 18 years * Patient meets the general criteria for severe sepsis or septic shock, diagnosed less than 48 h prior to study inclusion (see appendix A; in Dutch). * Patient must be relatively hemodynamically stable, defined as ...

Unlock Eligibility Criteria

Competitive Landscape -Sepsis 24 trials

Top 3 of 7 competitors

CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN1PHASE2AZD4144
ImmunityBio IncIBRX2PHASE2Nogapendekin alfa inbakicept
BayerBAYRY2PHASE1BAY 3389934
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Novartis AG (NVS)Pipeline, catalysts, financials, insiders and newsSepsis disease mapEvery company developing for Sepsis, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with LCompanies A to ZEvery biotech and pharma company we track